Helen Turner - Publications
Affiliations: | 1998-2001 | University of Oxford, Oxford, United Kingdom |
Year | Citation | Score | |||
---|---|---|---|---|---|
2018 | Woodcock VK, Clive S, Wilson RH, Coyle VM, Stratford MRL, Folkes LK, Eastell R, Barton C, Jones P, Kazmi-Stokes S, Turner H, Halford S, Harris AL, Middleton MR. A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer. PMID 29438361 DOI: 10.1038/bjc.2017.484 | 0.344 | |||
2013 | Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, ... ... Turner H, et al. A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 72: 1343-52. PMID 24141375 DOI: 10.1007/s00280-013-2320-9 | 0.395 | |||
Show low-probability matches. |